Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

You have to ask yourself what the company meant by "end". I think they meant achieving the results needed to reach stat. sig. in overall survival which will happen at the 2nd interim analysis. I can assure you that there's almost 0% chance of 600 SUNRISE patients being enrolled and evented/cured/censored by December 2016. The trial would have to have been fully enrolled already. That would be a sweet PR.

The Sorafenib phase 3 trial halted (ended) after the 2nd interim look-in...which occurred one year after enrollment was complete.

http://pharma.bayer.com/scripts/pages/en/news_room/news_room/news_room20.php

It had 600 patients and MOS was 7 months vs. 10 months...very similar life expectancy to SUNRISE. But that trial had 178 locations and was run by Bayer. Enrollment projections here without a partner are unrealistic IMO.